Researchers uncover the role of PAD4 in cancers
8 February 2016 | By Victoria White
Peptidyl arginine deiminase 4 (PAD4) is a protein that plays a role in the development of inflammatory diseases like arthritis...
List view / Grid view
8 February 2016 | By Victoria White
Peptidyl arginine deiminase 4 (PAD4) is a protein that plays a role in the development of inflammatory diseases like arthritis...
20 January 2016 | By Victoria White
Through the Phenotypic Discovery Initiative (PDi), partners will build robust, disease-relevant phenotypic assays with a focus on human-derived systems with the aim of identifying new drug targets and hit molecules.
19 October 2015 | By Victoria White
Genomics has entered into a collaboration agreement in a research project focused on the translation of whole genome sequencing into clinical practice...
5 October 2015 | By Victoria White
Initial studies by Oxford University researchers show that targeting the protein, called PAT4, could restrict cancerous cells' ability to grow...
4 September 2015 | By Oxford Global
In the run up to our 2015 Next Generation Sequencing Congress, Single Cell Congress & Genome Editing Congress we spoke with Jacqueline Boultwood, University of Oxford, a confirmed speaker at the congress, about her thoughts on the current status of the sequencing industry...
17 July 2015 | By Oxford Global
In the run up to our 2015 Next Generation Sequencing Congress, Single Cell Congress & Genome Editing Congress we spoke with Jacqueline Boultwood, University of Oxford...
15 July 2015 | By Victoria White
Scientists have shown that gene therapy can give protection to the light-sensitive photoreceptor cells responsible for colour vision in retinitis pigmentosa...
13 July 2015 | By Victoria White
Summit Therapeutics has announced the publication of preclinical data on the disease-modifying potential of utrophin modulation in the treatment of DMD...
Clearly what is needed is a synergistic collaboration bringing together the respective competence and expertise of academia and industry. All the major pharmaceutical companies have recognised this need and have introduced a range of different models for association with academia and small biotech or biopharma companies. Attempted solutions range from…
The ability to individualise a patient’s care has become a particularly pressing issue in the field of cancer therapeutics as there is a growing recognition that both the global incidence of cancer is steadily rising and the associated costs in terms of treatment and lost productivity are ever increasing. Advances…